This MedLibrary.org supplementary page on CD22 is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
|
CD22 molecule
|
||||||||||||||
| Identifiers | ||||||||||||||
| Symbols | CD22; MGC130020; SIGLEC-2; SIGLEC2 | |||||||||||||
| External IDs | OMIM: 107266 MGI: 88322 HomoloGene: 31052 | |||||||||||||
|
||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 933 | 12483 | ||||||||||||
| Ensembl | ENSG00000012124 | ENSMUSG00000030577 | ||||||||||||
| Uniprot | P20273 | Q3T9T5 | ||||||||||||
| Refseq | NM_001771 (mRNA) NP_001762 (protein) |
NM_001043317 (mRNA) NP_001036782 (protein) |
||||||||||||
| Location | Chr 19: 40.51 - 40.53 Mb | Chr 7: 30.57 - 30.59 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
CD22 or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins.[1] Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.
CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signalling.
EBV (Epstein-Barr virus) is known to bind to the B lymphocyte via the CD22 receptor.
An immunotoxin, BL22, that targets this receptor is being tested at the NIH.[2]
External links
References
- ^ Crocker PR, Clark EA, Filbin M, Gordon S, Jones Y, Kehrl JH, Kelm S, Le Douarin N, Powell L, Roder J, Schnaar RL, Sgroi DC, Stamenkovic K, Schauer R, Schachner M, van den Berg TK, van der Merwe PA, Watt SM, Varki A (1998). "Siglecs: a family of sialic-acid binding lectins". Glycobiology 8 (2): v. doi:. PMID 9498912.
- ^ "BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia". ClinicalTrials.gov - U.S. National Institutes of Health. Retrieved on 2008-02-19.
|
|||||||||||
|
|||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 10 August 2008, at 03:54.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "CD22".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.
